Bonuccelli U, D'Antonio P, D'Avino C, Piccini P, Muratorio A
Institute of Clinical Neurology, University of Pisa, Italy.
J Neural Transm Suppl. 1995;45:239-45.
In the last 20 years dopamine agonists have been considered more and more helpful as primary therapy for Parkinson's disease (PD). Recently the neuroprotective activity and the therapeutic efficacy of a new ergot derivative, alpha-dihydroergocryptine (DHEC), has been highlighted. In the present work we resume the experimental and clinical data reported about this drug. The rationale for dopamine (DA) agonists as primary therapy for Parkinson's disease (PD) is based on the possibility to delay the onset of long term I-dopa syndrome (LTS) (King, 1992); moreover DA agonists seem to exert a neuroprotective effect on substantia nigra neurons. In fact, they stimulate DA receptors bypassing the degenerating nigrostriatal neurons and their metabolic machinery (Lieberman, 1992; Olanow, 1992); more recently, some studies have shown that these drugs have a direct protective effect too (Felten et al., 1992; Yoshikawa et al., 1994). In this minireview we resume the data reported about neuroprotective activity and therapeutic efficacy of a new ergot derivative, alpha-dihydroergocryptine (DHEC).
在过去20年里，多巴胺激动剂作为帕金森病（PD）的主要治疗方法越来越受到重视。最近，一种新的麦角衍生物α-二氢麦角隐亭（DHEC）的神经保护活性和治疗效果得到了突出。在本研究中，我们总结了已报道的关于该药物的实验和临床数据。多巴胺（DA）激动剂作为帕金森病（PD）主要治疗方法的理论依据是有可能延迟长期左旋多巴综合征（LTS）的发生（King，1992）；此外，DA激动剂似乎对黑质神经元具有神经保护作用。事实上，它们通过绕过退化的黑质纹状体神经元及其代谢机制来刺激DA受体（Lieberman，1992；Olanow，1992）；最近，一些研究表明这些药物也具有直接的保护作用（Felten等，1992；Yoshikawa等，1994）。在本综述中，我们总结了已报道的关于一种新的麦角衍生物α-二氢麦角隐亭（DHEC）的神经保护活性和治疗效果的数据。
